Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474706 | 0.93 | SMN1; SMN2 (0.50) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1934000 | 0.93 | SMN1; SMN2 (0.50) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1190472 | 0.91 | PREP (0.49) | PREPACE2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18428254 | 0.88 | PREP (0.48) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL928649 | 0.86 | HTR2C (0.50) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30065232 | 0.81 | SMN1; SMN2 (0.51) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18599811 | 0.81 | PREP (0.52) | PREPACE2CTRB1RAB9ANPC1 | |
| SCHEMBL16250272 | 0.80 | PREP (0.47) | PREPACE2HSD17B10RAB9ANPC1 | |
| SCHEMBL15218168 | 0.80 | HTR2C (0.49) | PREPRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17722317 | 0.80 | PREP (0.47) | PREPACE2HSD17B10RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085525-B | Isoquinolin sulfonyl derivative as RHO kinase inhibitor | 南京明德新药研发股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | disclosed |
| US-9856264-B2 | Isoquinolinesulfonyl derivative as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | PREP 1333/4885ACE2 1661/4885HSD17B10 3610/4885 |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | PREP 3040/4885ACE2 1068/4885HSD17B10 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.